Antibacterials: metabolism accelerated by rifabutin and rifampicin – avoid with rifabutin; possibly increased rifabutin concentration – reduce rifabutin dose; clarithromycin can increase itraconazole concentration
Anticoagulants: effect of coumarins enhanced
Antidepressants: avoid concomitant use with reboxetineAntidiabetics: can enhance effects of repaglinide
Anti-epileptics: concentration reduced by carbamazepine, barbiturates and phenytoin – avoid with phenytoinAntihistamines: inhibits mizolastine metabolism – avoid concomitant use
Antimalarials: avoid concomitant use with artemether/lumefantrine
Antipsychotics: possibly inhibits metabolism of aripiprazole – reduce aripiprazole dose; increased risk of ventricular arrhythmias with pimozide and sertindole – avoid concomitant use; possibly increased quetiapine concentration – reduce quetiapine dose
Antivirals: concentration possibly increased by amprenavir; concentration of indinavir increased – may need to reduce indinavir dose; with ritonavir concentration of both drugs may be increased; concentration of saquinavir possibly increased; concentration reduced by efavirenzAnxiolytics and hypnotics: concentration of buspirone, midazolam and alprazolam increased – reduce buspirone doseBosentan: possibly increased bosentan concentration
Calcium-channel blockers: negative inotropic effect possibly increased; metabolism of felodipine and possibly dihydropyridines inhibited; avoid concomitant use with lercanidipine and nisoldipineCardiac glycosides: concentration of digoxin increased
Ciclosporin: metabolism of ciclosporin inhibited (increased plasma ciclosporin levels)Cytotoxics: metabolism of busulfan inhibited, increased risk of toxicity; possibly inhibits metabolism of vincristine, increased risk of neurotoxicity; possibly increased side effects with cyclophosphamide
Diuretics: increased eplerenone levels – avoid concomitant use
Ergot alkaloids: increased risk of ergotism – avoid concomitant use5HT 1 agonists: increased eletriptan concentration – avoid concomitant useIvabradine: possibly increased ivabradine levels – reduce initial doseLipid-lowering drugs: increased risk of myopathy with atorvastatin and .iTrAConAZoLE 403simvastatin – avoid concomitant use with simvastatin, and maximum atorvastatin dose 40 mg.1Sirolimus: concentration increased by itraconazole
Tacrolimus: possibly increased tacrolimus levels
Ulcer-healing drugs: absorption reduced by histamine H2 antagonists and proton pump inhibitors
Vardenafil: possibly increased vardenafil concentration – avoid concomitant use
ADMINISTRATION
Reconstition
–
Route
Oral,
IV infusion
Rate of Administration
Over 60 minutes
Comments
Add 250 mg vial to 50 mL sodium chloride 0.9%, administer 60 mL (increased volume due to large displacement value)
OTHER INFORMATION
Preparations absorbed at different rates: liquid is absorbed within 2.5 hours, capsules within 2–5 hoursOral bioavailability of itraconazole may be lower in some patients with renal insufficiency, e.g. those receiving CAPD Janssen-Cilag advise no dose alterations required in renal impairment as drug is extensively metabolised in the liver, and pharmacokinetics are unchanged in patients with ERF compared to normal
